Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: A multicenter prospective Phase II trial

Jason Chia Hsun Hsieh, Cheng Lung Hsu, Shu Hang Ng, Cheng Hsu Wang, Kuan Der Lee, Chang Hsien Lu, Yi Fang Chang, Ruey Kuen Hsieh, Kun Huei Yeh, Chi Huang Hsiao, Sheng Yu Chen, Cheng Ying Shiau, Hung Ming Wang

研究成果: 雜誌貢獻文章同行評審

12 引文 斯高帕斯(Scopus)

摘要

Objective: This multicenter Phase II trial evaluated the toxicity/efficacy of gemcitabine plus cisplatin as first-line chemotherapy in patients with recurrent/metastatic nasopharyngeal carcinoma. Methods: Gemcitabine 1250 mg/m2 on Days 1 and 8 and cisplatin 75 mg/m2 on Day 1 were administered at a 3-week interval. The primary endpoint was the response rate. Secondary endpoints included progression-free survival, overall survival, response duration and safety. Results: Fifty-two patients were recruited between 2004 and 2008. The response rate was 51.9% (complete remission rate, 9.6%) in the intent-to-treat group. The median progression-free and overall survivals were 9.8 and 14.6 months, respectively. The major Grade III/IV adverse event was leucopenia (61.6%). The mean number of cycleswas 6.63 ± 0.40. The regimenwaswell-tolerated, although one treatment-related death occurred after severe sepsis from aspiration pneumonia. Conclusions: Gemcitabine plus cisplatin is an effective, well-tolerated regimen as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma.
原文英語
文章編號hyv083
頁(從 - 到)819-827
頁數9
期刊Japanese Journal of Clinical Oncology
45
發行號9
DOIs
出版狀態已發佈 - 九月 1 2015
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 放射學、核子醫學和影像學
  • 癌症研究

指紋

深入研究「Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: A multicenter prospective Phase II trial」主題。共同形成了獨特的指紋。

引用此